eligibility_summary
Adults 18–80 with relapsed/refractory NHL (LBCL incl DLBCL, PMBCL, HGBCL, FL3B, FL, MZL, MCL) after ≤1 prior CD19 CAR‑T, ECOG 0–1, ≥1 PET‑positive measurable lesion, life expectancy ≥12 weeks. Exclude prior CD22‑directed therapy (incl CAR‑T/NK), CNS lymphoma within 1 year, autologous HSCT <3 months before LD chemo or any allogeneic HSCT, active autoimmune disease, need for immunosuppression or steroids >10 mg/d, and CNS disorders within 12 months.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
VIVID (NCT06285422) tests SC262, a hypoimmune, allogeneic CD22-directed CAR T-cell therapy, in relapsed/refractory NHL. After standard lymphodepletion with cyclophosphamide (alkylating chemotherapy) and fludarabine (purine analog antimetabolite), patients receive IV SC262. Mechanism: donor-derived T cells engineered with an anti-CD22 chimeric antigen receptor bind CD22 on B cells, triggering T-cell activation and cytotoxic killing of malignant B cells, the hypoimmune design aims to evade host immune rejection and enhance persistence. Conditioning drugs deplete lymphocytes to promote CAR T expansion. Target cells/pathways: CD22+ B-cell malignancies (LBCL, DLBCL, PMBCL, HGBCL, FL, MZL, MCL), engagement of CD22 on B cells and downstream T-cell effector pathways.